Perioperative Management of Endocrine Active Adrenal Tumors

Florentine Schreiner; Gurpreet Anand; Felix Beuschlein

doi:10.1055/a-0654-5251

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2019; 127(02/03): 137-146
DOI: 10.1055/a-0654-5251

Review

Perioperative Management of Endocrine Active Adrenal Tumors

Florentine Schreiner^*

¹Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland

,

Gurpreet Anand^*

¹Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland

,

Felix Beuschlein

¹Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland

²Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany

› Institutsangaben

Abstract

Endocrine active adrenal tumors are associated with a relevant risk of complications during surgery, either due to direct hemodynamic effects of the hormone excess or due to hormone related comorbidities. Over the last decades, careful preoperative evaluation and improved peri-interventional medical management of affected patients has resulted in a significant reduction of perioperative complications. In addition, improvement in anesthesia and surgical techniques with the feasibility of laparoscopic adrenalectomy have contributed to reduce morbidity. Nevertheless, there are still several challenges to be considered in the perioperative care of these patients. Due to the rarity of functionally active adrenal tumors, there are no prospective data available to guide clinical management. Accordingly, most recommendations are based on retrospective data analysis, expert opinion or carry weak evidence based on small series or case reports. The aim of this review is to summarize the current knowledge and to suggest practical approaches to reduce perioperative complications in endocrine active adrenal tumors. This review exclusively deals with data from adult patients with functionally active adrenal tumors.

Key words

pheochromocytoma - paraganglioma - primary aldosteronism - Cushing’s syndrome - surgery - laparoscopy - perioperative management

Volltext

Referenzen

References
1 Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359-369
2 Chen H, Sippel RS, O’Dorisio MS. et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775-783 doi:10.1097/MPA.0b013e3181ebb4f0
3 van Duinen N, Corssmit EP, de Jong WH. et al Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24- h urinary excretion rates of catecholamines and metabolites. Eur J Endocrinol 2013; 169: 377-382 doi:10.1530/EJE-13-0529
4 Riester A, Weismann D, Quinkler M. et al. Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol 2015; 173: 757-764 doi:10.1530/EJE-15-0483
5 Weismann D, Fassnacht M, Weinberger F. et al. Intraoperative haemodynamic stability in patients with phaeochromocytoma--minimally invasive vs conventional open surgery. Clin Endocrinol (Oxf) 2006; 65: 352-358 doi:10.1111/j.1365-2265.2006.02603.x
6 Lenders JW, Duh QY, Eisenhofer G. et al Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942 doi:10.1210/jc.2014-1498
7 Kopetschke R, Slisko M, Kilisli A. et al. Frequent incidental discovery of phaeochromocytoma: Data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161: 355-361 doi:10.1530/EJE-09-0384
8 Pacak K, Tella SH. Pheochromocytoma and Paraganglioma. In: De Groot LJ, Chrousos G, Dungan K. et al. eds Endotext. South Dartmouth (MA): 2000
9 Isaacs M, Lee P. Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: Is it always necessary?. Clin Endocrinol (Oxf) 2017; 86: 309-314 doi:10.1111/cen.13284
10 Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006; 1073: 405-416 doi:10.1196/annals.1353.044
11 Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069-4079 doi:10.1210/jc.2007-1720
12 Osranek M, Bursi F, Gura GM. et al. Echocardiographic features of pheochromocytoma of the heart. Am J Cardiol 2003; 91: 640-643
13 Goldstein RE, O'Neill Jr. JA, Holcomb 3rd GW. et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229: 755-764 discussion 764-756
14 Livingstone M, Duttchen K, Thompson J. et al. Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades. Ann Surg Oncol 2015; 22: 4175-4180 doi:10.1245/s10434-015-4519-y
15 Song G, Joe BN, Yeh BM. et al. Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. Int Braz J Urol 2011; 37: 35-40 discussion 40-31
16 Kota SK, Kota SK, Panda S. et al. Pheochromocytoma: an uncommon presentation of an asymptomatic and biochemically silent adrenal incidentaloma. Malays J Med Sci 2012; 19: 86-91
17 Lafont M, Fagour C, Haissaguerre M. et al. Per-operative hemodynamic instability in normotensive patients with incidentally discovered pheochromocytomas. J Clin Endocrinol Metab 2015; 100: 417-421 doi:10.1210/jc.2014-2998
18 Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 2002; 26: 1037-1042 doi:10.1007/s00268-002-6667-z
19 Kocak S, Aydintug S, Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas. Int Surg 2002; 87: 191-194
20 Weingarten TN, Cata JP, O'Hara JF. et al. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology 2010; 76: 508 e506-508 e511 doi:10.1016/j.urology.2010.03.032
21 Proye C, Thevenin D, Cecat P. et al. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery 1989; 106: 1149-1154
22 Combemale F, Carnaille B, Tavernier B. et al. [Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and per-operative management of pheochromocytomas. 70 cases]. Ann Chir 1998; 52: 341-345
23 Takahashi S, Nakai T, Fujiwara R. et al. Effectiveness of long-acting nifedipine in pheochromocytoma. Jpn Heart J 1989; 30: 751-757
24 Steinsapir J, Carr AA, Prisant LM. et al. Metyrosine and pheochromocytoma. Arch Intern Med 1997; 157: 901-906
25 Perry RR, Keiser HR, Norton JA. et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg 1990; 212: 621-628
26 Wachtel H, Kennedy EH, Zaheer S. et al. Preoperative Metyrosine Improves Cardiovascular Outcomes for Patients Undergoing Surgery for Pheochromocytoma and Paraganglioma. Ann Surg Oncol 2015; 22 (Suppl. 03) S646-S654 doi:10.1245/s10434-015-4862-z
27 Fernandez-Cruz L, Taura P, Saenz A. et al. Laparoscopic approach to pheochromocytoma: Hemodynamic changes and catecholamine secretion. World J Surg 1996; 20: 762-768 discussion 768
28 Agarwal G, Sadacharan D, Aggarwal V. et al. Surgical management of organ-contained unilateral pheochromocytoma: Comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series. Langenbecks Arch Surg 2012; 397: 1109-1116 doi:10.1007/s00423-011-0879-3
29 Shen WT, Grogan R, Vriens M. et al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg 2010; 145: 893-897 doi:10.1001/archsurg.2010.159
30 Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab 2006; 20: 483-499 doi:10.1016/j.beem.2006.07.010
31 Lee CR, Walz MK, Park S. et al. A comparative study of the transperitoneal and posterior retroperitoneal approaches for laparoscopic adrenalectomy for adrenal tumors. Ann Surg Oncol 2012; 19: 2629-2634 doi:0.1245/s10434-012-2352-0
32 Castillo OA, Lopez-Fontana G, Vitagliano G. Laparoscoscopic synchronous bilateral adrenalectomy. Arch Esp Urol 2011; 64: 114-120
33 Asari R, Scheuba C, Kaczirek K. et al. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2 A. Arch Surg 2006; 141: 1199-1205 discussion 1205 doi:10.1001/archsurg.141.12.1199
34 Shen WT, Sturgeon C, Clark OH. et al Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004; 136: 1129-1137 doi:10.1016/j.surg.2004.05.058
35 Rafat C, Zinzindohoue F, Hernigou A. et al. Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery. J Clin Endocrinol Metab 2014; 99: E2681-E2685 doi:10.1210/jc.2014-1975
36 Li N, Kong H, Li SL. et al. Combined epidural-general anesthesia was associated with lower risk of postoperative complications in patients undergoing open abdominal surgery for pheochromocytoma: A retrospective cohort study. PLoS One 2018; 13: e0192924 doi:10.1371/journal.pone.0192924
37 Chambers S, Espiner EA, Donald RA. et al. Hypoglycaemia following removal of phaeochromocytoma: Case report and review of the literature. Postgrad Med J 1982; 58: 503-506
38 Meeke RI, O'Keeffe JD, Gaffney JD. Phaeochromocytoma removal and postoperative hypoglycaemia. Anaesthesia 1985; 40: 1093-1096
39 Plouin PF, Amar L, Dekkers OM. et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 2016; 174: G1-G10 doi:10.1530/EJE-16-0033
40 Funder JW, Carey RM, Mantero F. et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916 doi:10.1210/jc.2015-4061
41 Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies – a review of the current literature. Horm Metab Res 2012; 44: 157-162 doi:10.1055/s-0031-1295438
42 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300 doi:10.1016/j.jacc.2006.07.059
43 Monticone S, D'Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50 doi:10.1016/S2213-8587(17)30319-4
44 Rossi GP, Cesari M, Cuspidi C. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-69 doi:10.1161/HYPERTENSIONAHA.113.01316
45 Fischer E, Hanslik G, Pallauf A. et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-3973 doi:10.1210/jc.2012-2234
46 Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus open adrenalectomy for surgical adrenal disease. Can J Urol 2003; 10: 1995-1999
47 Nanba AT, Nanba K, Byrd JB. et al. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol (Oxf) 2017; 87: 665-672 doi:10.1111/cen.13442
48 Pautler SE, Choyke PL, Pavlovich CP. et al. Intraoperative ultrasound aids in dissection during laparoscopic partial adrenalectomy. J Urol 2002; 168: 1352-1355 doi:10.1097/01.ju.0000031272.56889.28
49 Reimel B, Zanocco K, Russo MJ. et al. The management of aldosterone-producing adrenal adenomas--does adrenalectomy increase costs?. Surgery 2010; 148: 1178-1185 discussion 1185 doi:10.1016/j.surg.2010.09.012
50 Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg 2002; 89: 1587-1593 doi:10.1046/j.1365-2168.2002.02261.x
51 Kim AW, Quiros RM, Maxhimer JB. et al. Outcome of laparoscopic adrenalectomy for pheochromocytomas vs aldosteronomas. Arch Surg 2004; 139: 526-529 discussion 529-531 doi:10.1001/archsurg.139.5.526
52 Sechi LA, Colussi G, Di Fabio A. et al. Cardiovascular and renal damage in primary aldosteronism: Outcomes after treatment. Am J Hypertens 2010; 23: 1253-1260 doi:10.1038/ajh.2010.169
53 Reincke M, Rump LC, Quinkler M. et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 869-875 doi:10.1210/jc.2008-1851
54 Arlt W, Lang K, Sitch AJ. et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017; 2
55 Williams TA, Lenders JWM, Mulatero P. et al Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699 doi:10.1016/S2213-8587(17)30135-3
56 Nieman LK, Biller BM, Findling JW. et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831 doi:10.1210/jc.2015-1818
57 Lindholm J, Juul S, Jorgensen JO. et al. Incidence and late prognosis of cushing's syndrome: A population-based study. J Clin Endocrinol Metab 2001; 86: 117-123 doi:10.1210/jcem.86.1.7093
58 Pivonello R, Isidori AM, De Martino MC. et al. Complications of Cushing's syndrome: State of the art. Lancet Diabetes Endocrinol 2016; 4: 611-629 doi:10.1016/S2213-8587(16)00086-3
59 Porterfield JR, Thompson GB, Young Jr. WF. et al. Surgery for Cushing's syndrome: An historical review and recent ten-year experience. World J Surg 2008; 32: 659-677 doi:10.1007/s00268-007-9387-6
60 Oosterhuis JK, van den Berg G, Monteban-Kooistra WE. et al. Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome. Neth J Med 2007; 65: 215-217
61 Stuijver DJ, van Zaane B, Feelders RA. et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: A multicenter cohort study. J Clin Endocrinol Metab 2011; 96: 3525-3532 doi:10.1210/jc.2011-1661
62 Van Zaane B, Nur E, Squizzato A. et al. Hypercoagulable state in Cushing’s syndrome: A systematic review. J Clin Endocrinol Metab 2009; 94: 2743-2750 doi:10.1210/jc.2009-0290
63 Koutroumpi S, Daidone V, Sartori MT. et al. Venous thromboembolism in patients with Cushing's syndrome: Need of a careful investigation of the prothrombotic risk profile. Pituitary 2013; 16: 175-181 doi:10.1007/s11102-012-0398-4
64 van der Pas R, Leebeek FW, Hofland LJ. et al. Hypercoagulability in Cushing's syndrome: Prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78: 481-488 doi:10.1111/cen.12094
65 Boscaro M, Sonino N, Scarda A. et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87: 3662-3666 doi:10.1210/jcem.87.8.8703
66 Berr CM, Stieg MR, Deutschbein T. et al. Persistence of myopathy in Cushing's syndrome: Evaluation of the German Cushing's Registry. Eur J Endocrinol 2017; 176: 737-746 doi:10.1530/EJE-16-0689
67 Rayes N, Quinkler M, Denecke T. [Surgical strategies for non-metastatic adrenocortical carcinoma]. Chirurg 2018; 89: 434-439 doi:10.1007/s00104-017-0582-1
68 Berr CM, Di Dalmazi G, Osswald A. et al. Time to recovery of adrenal function after curative surgery for Cushing's syndrome depends on etiology. J Clin Endocrinol Metab 2015; 100: 1300-1308 doi:10.1210/jc.2014-3632
69 Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev 2003; 24: 523-538 doi:10.1210/er.2001-0014
70 Petersenn S, Honegger J, Quinkler M. National German Audit of Diagnosis, Treatment, and Teaching in Secondary Adrenal Insufficiency. Horm Metab Res 2017; 49: 580-588 doi:10.1055/s-0043-105077
71 Clayton RN, Jones PW, Reulen RC. et al. Mortality in patients with Cushing's disease more than 10 years after remission: A multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4: 569-576 doi:10.1016/S2213-8587(16)30005-5
72 Bolland MJ, Holdaway IM, Berkeley JE. et al Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf) 2011; 75: 436-442 doi:10.1111/j.1365-2265.2011.04124.x